GlassScriptPhysician profile
Justin J Pi
NPI 1427203306
$5,247.46
in general payments reported to CMS, 2019-2025
42 companies · $1,281 in 2025
The $1,281 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,312 · 2020: $203 · 2021: $11.04 · 2022: $449 · 2023: $873 · 2024: $1,119 · 2025: $1,281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,989 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,988.76 |
| Education | $284.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $827.63 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $489.26 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Harmony Biosciences LLC | $468.77 | 2022-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $431.38 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $309.00 | 2019-2020 | |
| Axsome Therapeutics, INC. | $290.21 | 2023-2025 | Sunosi |
| Regeneron Healthcare Solutions, INC. | $210.86 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $198.74 | 2020-2025 | Aralast |
| Inspire Medical Systems, INC. | $177.66 | 2023-2025 | Inspire |
| Genzyme Corporation | $169.03 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.42 | 2019-2024 | Ofev |
| Mylan Specialty L.P. | $160.33 | 2019-2024 | Yupelri |
| Insmed, INC. | $129.55 | 2019-2025 | Arikayce |
| Electromed, INC. | $110.25 | 2023-2025 | Smartvest |
| Novartis Pharmaceuticals Corporation | $109.40 | 2019-2023 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $94.66 | 2019-2025 | Prolastin-C Liquid, Gamunex-C |
| Avadel Cns Pharmaceuticals, LLC | $94.31 | 2023-2025 | Lumryz |
| Philips North America LLC | $77.68 | 2019-2025 | Vest Therapy Und |
| E.R. Squibb & Sons, L.L.C. | $62.82 | 2019-2022 | |
| Lilly USA, LLC | $58.56 | 2025 | Zepbound |
| Mallinckrodt Enterprises LLC | $57.03 | 2019 | |
| Genentech USA, INC. | $52.48 | 2022-2025 | Ocrevus Zunovo, Xolair |
| Viatris Specialty LLC | $51.03 | 2025 | Yupelri |
| United Therapeutics Corporation | $46.61 | 2019-2025 | Tyvaso, Tyvaso |
| Sk Life Science, INC. | $36.91 | 2023-2024 | |
| Argenx US, INC. | $36.62 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Vapotherm INC | $34.50 | 2019 | |
| Amgen INC. | $31.69 | 2023 | Tezspire |
| Abbvie INC. | $29.75 | 2024 | |
| Shire North American Group INC | $29.05 | 2019 | |
| Pfizer INC. | $25.47 | 2019 | |
| Baxter Healthcare | $21.37 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Hospital Products INC. | $19.93 | 2024 | Acthar |
| Verona Pharma, INC. | $18.29 | 2025 | Ohtuvayre |
| Xeris Pharmaceuticals, INC. | $17.33 | 2024 | Keveyis |
| Resmed Corp | $17.19 | 2019 | |
| Chiesi USA, INC. | $16.32 | 2025 | Cleviprex |
| Ani Pharmaceuticals, INC. | $15.79 | 2023 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $15.16 | 2023 | Belsomra |
| Astellas Pharma US INC | $14.58 | 2019 | |
| Circassia INC. | $14.27 | 2019 | |
| Aytu Biopharma, INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Pi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.